Q
Quantum BioPharma Ltd. (QNTM)
NCM – Real vaqt narxi. Valyuta: USD
5.20
+0.14 (2.77%)
Yopilishda: May 12, 2026, 4:00 PM EDT
5.20
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 8:48 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
5.20
+0.14 (2.77%)
Yopilishda: May 12, 2026, 4:00 PM EDT
5.20
0.00 (0.00%)
Bozor oldidan: May 13, 2026, 8:48 AM EDT
Quantum BioPharma Ltd. o'z sho'ba korxonalari bilan birgalikda biofarmatsevtika kompaniyasi sifatida faoliyat yuritadi. Kompaniya Biopharmatsevtika innovatsiyalari va Strategik investitsiyalar kabi ikkita segment orqali ishlaydi. U neyrodegenerativ, yallig'lanish va metabolik kasalliklar, shuningdek, spirtli ichimliklarni suiiste'mol qilish bilan bog'liq buzilishlarni davolash uchun aktivlar va biotexnologik yechimlar portfelini tadqiq qiladi va ishlab chiqadi, bunda turli rivojlanish bosqichlaridagi dori nomzodlari mavjud. Kompaniyaning asosiy birikmasi Lucid-MS bo'lib, u patentlangan yangi kimyoviy moddadir va ko'p sklerozning asosiy mexanizmi bo'lgan mielin degradatsiyasini oldini olish va tiklash uchun preklinik modellar uchun 2-bosqichli klinik sinovdan o'tmoqda. Shuningdek, u mast hujayralarining faollashuvi sindromi kabi yallig'lanish kasalliklarini davolash uchun 2-bosqichli sinovga tayyorlanayotgan FSD-PEA; katta depressiv buzilishlarni davolash uchun Lucid-PSYCH; va spirtli ichimliklarni suiiste'mol qilishni davolash uchun parhez qo'shimchasi bo'lgan unbuzzdni ishlab chiqadi. Bundan tashqari, kompaniya turar-joy mulki bilan ta'minlangan kreditlardan iborat strategik investitsiyalar portfelini saqlaydi. Kompaniya ilgari FSD Pharma Inc. nomi bilan tanilgan va 2024-yil avgust oyida Quantum BioPharma Ltd. nomini o'zgartirgan. Quantum BioPharma Ltd. 1998-yilda tashkil etilgan va Toronto, Kanadada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Andrzej Chruscinski M.D., Ph.D. | Vice President of Clinical & Scientific Affairs |
| Dr. Ashwini Joshi M.S. | Director of Pharmaceutical Development |
| Dr. Lakshmi P. Kotra BPHARM, Ph.D. | President & Director |
| Dr. Patrick Onyango Ph.D. | Director of Operations at U.S. |
| Mr. Anthony John Durkacz | Co-Founder & Executive Non-Independent Co-Chairman |
| Mr. Donal Carroll CPA | Chief Financial Officer |
| Mr. Jason David Sawyer | Head of Finance & Mergers and Acquisitions |
| Mr. Nathan Coyle CPA | Controller |
| Mr. Zeeshan Saeed | Co-Founder, CEO & Executive Non-Independent Co-Chairman |
| Ms. Maryann Adesso | Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 6-K | f6k_050726.htm |
| 2026-05-06 | 6-K | qntm6k050426.htm |
| 2026-04-22 | 6-K | f6k_042226.htm |
| 2026-04-02 | 6-K | f6k_040126.htm |
| 2026-04-01 | 6-K | f6k_033126.htm |
| 2026-03-30 | 6-K | f6k_033026.htm |
| 2026-03-27 | 6-K | f6k_032626.htm |
| 2026-03-26 | 20-F | qntm20f123125.htm |
| 2026-03-23 | 6-K | f6k_032326.htm |
| 2025-12-23 | 6-K | f6k_122325.htm |